The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What challenges arise in the management of AML in complete remission?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Norbert Vey, Institut Paoli-Calmettes, Marseille, FR. We asked, What challenges arise in the management of AML in complete remission?

What challenges arise in the management of AML in complete remission?

Recent improvements in induction chemotherapy have resulted in 70–80% of patients reaching complete remission, however, the majority will eventually relapse. In this video, Vey discusses the challenges and corresponding solutions in managing relapse, including:

  •  patient-related factors, such as age, cytogenetics, secondary AML, and minimal residual disease
  • targeted therapies, such as venetoclax, as an alternative to standard consolidation
  • maintenance strategies, combining different agents for elderly patients with AML

 

Share: